Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23982861 | 1.00 | CHRM2 (0.40) | CHRM2CHRM1KMT2AMEN1CYP2D6 | |
| SCHEMBL25666112 | 1.00 | CHRM2 (0.40) | CHRM2CHRM1KMT2AMEN1CYP2D6 | |
| SCHEMBL22475427 | 1.00 | CHRM2 (0.40) | CHRM2CHRM1KMT2AMEN1CYP2D6 | |
| SCHEMBL2627321 | 1.00 | CHRM2 (0.40) | CHRM2CHRM1KMT2AMEN1CYP2D6 | |
| SCHEMBL20419315 | 1.00 | CHRM2 (0.40) | CHRM2CHRM1KMT2AMEN1CYP2D6 | |
| SCHEMBL10440862 | 0.84 | CHRM2 (0.42) | CHRM2CHRM1KMT2AMEN1CYP2D6 | |
| SCHEMBL24260319 | 0.84 | CHRM2 (0.38) | CHRM2CHRM1KMT2AMEN1CYP2D6 | |
| SCHEMBL24752327 | 0.84 | CHRM2 (0.38) | CHRM2CHRM1KMT2AMEN1CYP2D6 | |
| SCHEMBL17294429 | 0.84 | CHRM2 (0.38) | CHRM2CHRM1KMT2AMEN1CYP2D6 | |
| SCHEMBL24792569 | 0.84 | CHRM2 (0.38) | CHRM2CHRM1KMT2AMEN1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10443035-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEATTLE GENETICS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180155677-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEAGEN INC. | 2018-06-07 | — | — | US | disclosed |
| US-6211107-B1 | Process for expoxidizing prochiral olefins and a catalyst therefor and intermediates for making the catalyst | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-04-03 | — | — | US | disclosed |
| US-5616750-A | Compounds and process | SMITHKLINE BEECHAM PLC (GB) | 1997-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155677-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | FUT5, FUCA2, FCGR3B | CHRM2 4627/4885CHRM1 4709/4885KMT2A 907/4885 |
| US-10443035-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | FUT5, FUCA2, FCGR3B | CHRM2 4627/4885CHRM1 4709/4885KMT2A 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.